ADC Therapeutics SA vs Protalix Biotherapeutics
ADC Therapeutics SA is the larger business, with $81.4m of revenue in fiscal 2025 against $52.7m for Protalix Biotherapeutics (1.5 times as much). ADC Therapeutics SA grew faster (14.9% against -1.2%). Protalix Biotherapeutics kept more of each dollar of sales as profit: a net margin of -12.5% against -175.3%.
| Latest fiscal year | ADC Therapeutics SAADCT, 2025 | Protalix BiotherapeuticsPLX, 2025 |
|---|---|---|
| Revenue | $81.4m | $52.7m |
| Revenue growth | 14.9% | -1.2% |
| Net income | −$143m | −$6.6m |
| Operating margin | -149.3% | -10.4% |
| Net margin | -175.3% | -12.5% |
| Return on equity | — | -14.4% |
| Free cash flow | −$141m | −$13.6m |
| Cash | $261m | $14.7m |
| Total debt | $116m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 188 | 226 |
| Market value | $198m | $203m |
| Price vs our value range | — | — |
| Moat score | — | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 6 sales | 1 buys, 1 sales |